We have treated 20 patients, affected by acute myelogenous leukemia in advanced phase of the disease, with intravenous high-dose recombinant interleukin-2 (IL2) as induction treatment, achieving a complete remission (CR) in 11/20 of patients (55%). All CR patients were planned to receive a maintenance program with lower subcutaneous doses of IL2 until relapse. Currently, 5/11 patients are alive in continuous complete remission with a minimum follow-up of 9 years from IL2 induction. In the aim to investigate the treatment's side-effects during or after prolonged IL2 therapy, we decided to submit these patients to a clinical and immunological evaluation. Four patients have been evaluated as one, who independently stopped IL2 after 6 years, refused the check-up. No organ-specific treatment sequelae that may decrease the quality of life or may be life-threatening were found, concerning renal, liver and cardiovascular function. Endocrine abnormalities were detected in three patients, the most serious being a severe hypothyroidism, which prompted cessation of IL2 maintenance after 6 years and required thyroid supplementation treatment. Immunological studies were carried out prior to the last IL2 cycle and showed high levels of CD3-positive T cells expressing the IL2 receptor alpha chain (CD25), both in the peripheral blood and in the bone marrow. Our study shows that low-dose IL2 can be given for a prolonged period of time without serious organ-specific late sequelae and with a good quality of life.
Introduction
Recombinant interleukin-2 (rIL2) is a biologic response modifier capable of activating cytotoxic T lymphocytes and natural killer (NK) cells and enhancing their cytotoxic activity against endogenous tumour cells. 1, 2 Clinical trials have indicated antileukemic activity of IL2 in patients with acute myeloid leukemia in relapse and in II CR, as consolidation therapy, for the elimination of minimal residual blast population to prolong disease-free survival. [3] [4] [5] [6] IL2 treatment is associated with a number of toxic sideeffects that involve virtually every organ system and which appears to be dose-related. Toxic effects during continuous administration of high-dose IL2, as fever, chills, nausea, vomiting, diarrhoea, dermatitis, oliguria, hypotention, fluid retention, cardiac arrhythmias, neuropsychiatric alterations, increase in circulating pituitary stress hormones (ACTH, prolactin and growth hormone) and increases in the incidence of bacteremia because of neutrophil chemotaxis deficiency, have been reported. [7] [8] [9] [10] [11] [12] Milder effects such as mild fever, fatigue, nausea and occasional vomiting have been observed following subcutaneously low-dose administration. No study has investigated the late side-effects after prolonged therapy with IL2. In 1988, we started to use IL2 for the management of acute myelogenous leukemia (AML), showing the feasibility and potential antileukemic activity of our IL2 schedule, in patients with limited bone marrow blastosis (Ͻ30%). [4] [5] [6] [7] [8] [9] [10] [11] [12] We treated 20 patients in advanced phase of disease, with less than 30% bone marrow blastosis, with intravenous high-dose IL2, achieving a complete remission (CR) in 11/20 (55%) patients. The initial purpose of our study was to test the possibility of obtaining durable responses in this group of patients, inducing a marked circulating and marrow immune activation by IL2. All CR patients entered a monthly maintenance program with lower doses of IL2 administered subcutaneously until relapse; the ultimate goal of maintenance therapy was to eradicate or arrest the development of residual clonogenic leukemia cells by using IL2 at the state of minimal residual disease, to increase cure rates and long-term survival. 13 Eleven patients entered the maintenance program and five of them showed an early relapse, still on therapy, with a median of 5 months (range 3-9 months); one patient was lost to follow-up, and 5/11 patients are alive in continuous complete remission with a minimum follow-up of 9 years. Because of absence of studies that investigate the treatment's sideeffects during or after prolonged IL2 therapy, these patients underwent an accurate check-up to evaluate whether sideeffects have been caused by long-term immunotherapy.
Patients and methods

Patients
Four of the five long-term surviving AML patients -one refused to undergo the check-up (this patient refused to continue immunotherapy 4 years ago, after 6 years of treatment) -three males and one female, median age 50.5 years (range 19-65) were considered in our study. All of them were in continuous complete remission with a follow-up duration of 9, 10, 10 and 13 years after IL2 treatment. One patient had been treated in first relapse (first CR obtained after two different induction schedule), one patient in second, one in third and one in fourth relapse. At the time of this study, one of the four patients had stopped treatment after 6 years because of toxicity 3 years ago; 3/4 patients are still on immunotherapy after 10, 10 and 13 years. The characteristics of the patients are shown in Table 1 .
Treatment plan
Reconstitution and administration modalities have been described in our previous report. 12 Briefly, the first patient was treated with Glaxo-IL2 (Glaxo, Geneva, Switzerland), whereas the others received EuroCetus-IL2 (Proleukin; Eurocetus, Amsterdam, The Netherlands). IL2 was administered intravenously by 24 h continuous infusion for 5 days, using a daily . Patients who achieved CR after IL2 entered a maintenance program, until relapse, consisting of monthly 5-day courses of lower doses of IL2 given by 6 h continuous intravenous infusion in the first patient and subcutaneously in the other patients. Glaxo doses were 100 g/m 2 on day 1 and 200 g/m 2 for 4 days after, whereas EuroCetus doses were 4 × 10 6 IU/m 2 on day 1 and 8 × 10 6 IU/m 2 on days 2 to 5. After the first year of maintenance treatment, EuroCetus IL2 was administered every other month for 2 years, then every 2 or 3 months at a lower dose (ranging from 4 to 8 × 10 6 IU/day total dose for 4 days) adjusted according to the patient's tolerance. Currently, the three patients still on treatment are receiving 4 × 10 6 IU/day for three days every four months.
Check-up
The following work-up program was implemented: (1) cardiovascular system was investigated by clinical cardiovascular examination, echocardiograms and ECG; (2) liver function was assessed by liver volumes, bilirubin levels, transaminase values and protein electrophoresis; (3) renal function was evaluated by serum electrolyte levels and creatinine values; (4) endocrine system was studied by thyroid function tests (FT3, FT4, TSH by microenzymeimmunoassay (MEIA)), pituitary stress hormone levels (ACTH and cortisol by radioimmunoassay (RIA), prolactin, LH and FSH by MEIA), androgens or estrogenic hormone levels (testosterone and progesterone by RIA, 17 beta estradiol by MEIA); (5) autoimmunity was evaluated by antithyroglobulin and antimicrosomal thyroid antibodies (RIA); antinuclear antibodies, anti-mitochondrial antibodies, anti-smooth muscle antibodies and anti-parietal cell antibodies (IFI), ena by (ELISA), anti-cardiolipin antibodies and anti-neutrophil cytoplasmic antibodies (ELISA); (6) immunologic evaluation: mononuclear peripheral blood and bone marrow cells were obtained after fractionation on a Lymphoprep gradient. Immunological studies consisted of flow cytometric analysis of the patient's mononuclear cells phenotype using a panel of conjugated monoclonal antibodies (Becton Dickinson): FITC-CD8/Pe-CD4/Pcp-CD3, FITC-CD16/Pe-CD56, and expression of the IL2 receptor alpha chain (FITC-CD25) on T lymphocytes. Immunologic evaluation was carried out on peripheral blood and bone marrow samples prior to the last IL2 cycle; (7) incidence of infection; (8) an accurate anamnesis allowed evaluation of possible neuropsychiatric alteration as behavioral changes and mood disLeukemia orders; (9) patients completed a questionnaire that elicited information about the quality of life, regarding history of hospitalization, medication, history of schooling and employment status.
Results
All patients are alive with a good quality of life: one patient studies at the university, two patients work and one retired 5 years ago. Cardiovascular examination showed a normal cardiac function in all patients; no hepatic or renal abnormalities were found. Endocrine abnormalities were found in three patients: one patient had a severe hypothyroidism requiring thyroid supplementation treatment and interruption of immunotherapy after 6 years, and had mildly decrease ACTH levels not requiring substitutive therapy; one patient had mildly elevated prolactin value and urinary cortisol levels; one patient had a mild decrease of testosterone levels and increase of FSH levels.
In all patients, we recorded an absence of systemic autoimmune disease or humoral immunity against thyroid antigens. No patient showed psychiatric side-effects as behavioral changes or mood disorders. No patient developed a particular susceptibility to infections and they did not need prophylactic antibiotic therapy.
Immunologic studies showed a normal CD4/CD8 ratio in bone marrow mononuclear cells (median value 1.4, range 0.8-1.5) and peripheral blood mononuclear cells (median value 1.3, range 1-1.9) in all patients, a normal percentage of NK cells both in the bone marrow (median value 6%, range 5-8%) and peripheral blood samples (median value 5%, range 4-7%) in three patients, while one patient, on treatment with IL2 for 13 years, showed an increase of NK cells both in the marrow (11%) and blood (14%). All the four patients presented high levels of CD3-positive T cells expressing the IL2 receptor alpha chain (CD25), both in the peripheral blood (range 13-42%) and in the bone marrow (range 12-34%).
Discussion
In 1988, we started to use IL2 by continuous infusion in the management of AML patients with advanced phase and limited bone marrow blastosis. We treated 20 patients and 11 achieved a complete remission; five out of 11 relapsed early after 3, 3, 5, 5 and 9 months, during maintenance treatment, while five out of 11 are alive in continuous complete remission after 9, 10, 10, 10 and 13 years and three of them have been on immunotherapy from 10, 10 and 13 years. In view of possible late side-effects due to prolonged IL2 administration, we set out to evaluate late changes in three long-term surviving patients after more than 10 years of treatment and in one patient who stopped therapy after 6 years, 3 years ago.
The results of the extensive work-up indicate that there are no organ-specific treatment sequelae that may decrease the quality of life or may be life-threatening. In all patients, including the one who suspended IL2 3 years ago, high levels of CD25-positive T lymphocytes were observed both in the bone marrow and peripheral blood. This suggests that prolonged immunotherapy with IL2 may contribute to a status of activation of T lymphocytes. We detected, in fact, normal renal, liver and cardiovascular function. We did not find neuropsychiatric side-effects and no patient developed susceptibility to infections. In contrast, we did observe endocrine alterations in 3/4 patients, the most serious being a severe hypothyroidism without immune pathogenesis after 6 years of treatment that prompted interruption of immunotherapy and still requires thyroid supplementation treatment.
Some studies have investigated in vitro and in vivo, in murine models, the effects of IL2 on the activation of the hypothalamic-pituitary-adrenal axis and testosterone synthesis and the results demonstrate that IL2 stimulates the basal release of prolactin, ACTH, cortisol and TSH, it suppresses the basal release of LH and FSH, and decreases testosterone production. Few studies in humans demonstrate that IL2 is able to activate the hypothalamus-pituitary-adrenal axis in vivo during IL2 administration.
Our study shows that the prolonged administration of lowdose of IL2 can be given without serious organ-specific late sequelae and with a good quality of life. Immunologic studies may suggest a prolonged activation of T lymphocytes; in fact, all patients presented high levels of the alpha chain of the IL2 receptor in bone marrow and peripheral blood samples, even 3 years after stopping therapy.
The results of endocrine studies showed heterogeneous alterations that, in the absence of baseline controls, do not permit establishment of a correlation with the immunotherapy. However, the effects of IL2 on the endocrine system reported in murine models, together with the changes hereby observed (and another experience reported in the literature), indicate that more studies are warranted.
